紫杉类联合铂类方案对比多柔比星联合顺铂作为高进展风险子宫内膜癌术后辅助化疗的随机临床试验
这项多中心、开放标签、3期随机临床试验纳入日本118家机构的788例高进展风险子宫内膜癌患者,随机接受多柔比星联合顺铂、多西他赛联合顺铂或紫杉醇联合卡铂6周期术后辅助化疗;中位随访7年,三组无进展生存和总生存均无统计学差异,三种方案耐受性无统计学差异但毒性不同,紫杉类联合铂类可作为多柔比星联合顺铂的合理替代。
要点
- 高进展风险子宫内膜癌术后辅助化疗中,紫杉类联合铂类与多柔比星联合顺铂的生存无显著差异。
- 中位随访7年,三组无进展生存P=0.12、总生存P=0.67,均无统计学差异。
- 三种方案耐受性无统计学差异但毒性不同,紫杉类联合铂类可能为合理替代。
核心结论
- 多柔比星联合顺铂、多西他赛联合顺铂或紫杉醇联合卡铂作为子宫内膜癌术后辅助化疗,患者生存无显著差异。
- 因每种方案耐受性可且毒性不同,紫杉类联合铂类方案可能是多柔比星联合顺铂治疗的合理替代。
研究设计与样本
- 多中心、开放标签、3期随机临床试验,纳入日本118家机构2006年11月24日至2011年1月7日的高危I期或II期或III期或IV期未超出腹腔且残留肿瘤≥2 cm的子宫内膜癌患者。
- 788例合格患者随机(1:1:1)接受6周期多柔比星60 mg/m²联合顺铂50 mg/m²(第1天)、多西他赛70 mg/m²联合顺铂60 mg/m²(第1天)或紫杉醇180 mg/m²联合卡铂(曲线下面积6.0 mg/mL×min)(第1天),每3周一次。
- 主要终点为无进展生存,次要终点为总生存、不良事件发生、耐受性和淋巴结清扫状态。
- 数据分析时间为2017年3月15日至2017年6月30日。
主要发现
- 788例合格患者中位(SD)年龄59(22-74)岁;多柔比星联合顺铂组263例、多西他赛联合顺铂组263例、紫杉醇联合卡铂组262例。
- 未完成6周期患者数:多柔比星联合顺铂组53例(20.1%)、多西他赛联合顺铂组45例(17.1%)、紫杉醇联合卡铂组63例(24.0%);各方案耐受性无统计学差异。
- 中位随访7年,无进展生存事件数:多柔比星联合顺铂组191、多西他赛联合顺铂组208、紫杉醇联合卡铂组187,P=0.12。
- 总生存事件数:多柔比星联合顺铂组217、多西他赛联合顺铂组223、紫杉醇联合卡铂组215,P=0.67。
- 5年无进展生存率:多柔比星联合顺铂组73.3%、多西他赛联合顺铂组79.0%、紫杉醇联合卡铂组73.9%;5年总生存率分别为82.7%、88.1%、86.1%。
临床怎么用
- 作者认为,紫杉类联合铂类方案可能是多柔比星联合顺铂治疗的合理替代。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The efficacy of taxane plus platinum regimens has been demonstrated for advanced or recurrent endometrial cancer; however, it has not been assessed in postoperative adjuvant chemotherapy for endometrial cancer. OBJECTIVE: To evaluate the clinical benefit of taxane plus platinum compared with standard doxorubicin plus cisplatin as postoperative adjuvant chemotherapy in endometrial cancer. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, open-label, phase 3 randomized clinical trial, patients with endometrial cancer at high-risk stage I or II or stage III or IV that did not extend beyond the abdominal cavity and had 2 cm or greater residual tumor were included from 118 institutions in Japan from November 24, 2006, to January 7, 2011. Data was analyzed from March 15, 2017, to June 30, 2017. INTERVENTIONS: Eligible patients were randomly assigned (1:1:1) to receive 6 cycles of doxorubicin, 60 mg/m2, plus cisplatin, 50 mg/m2, on day 1; docetaxel, 70 mg/m2, plus cisplatin, 60 mg/m2, on day 1; or paclitaxel, 180 mg/m2, plus carboplatin (area under the curve, 6.0 mg/mL × min) on day 1 every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival. Secondary end points were overall survival, occurrence of adverse events, tolerability, and status of lymph node dissection. RESULTS: Among 788 eligible patients, the median (SD) age was 59 (22-74) years; 263 patients were assigned to doxorubicin plus cisplatin treatment, 263 patients to docetaxel plus cisplatin treatment, and 262 patients to paclitaxel plus carboplatin treatment. The number of patients who did not complete 6 cycles was 53 (20.1%) for the doxorubicin plus cisplatin group, 45 (17.1%) for the docetaxel plus cisplatin group, and 63 (24.0%) for the paclitaxel plus carboplatin group. Tolerability of these regimens were not statistically different. After a median follow-up period of 7 years, there was no statistical difference of progression-free survival (doxorubicin plus cisplatin, 191; docetaxel plus cisplatin, 208; paclitaxel plus carboplatin, 187; P = .12) or overall survival (doxorubicin plus cisplatin, 217; docetaxel plus cisplatin, 223; paclitaxel plus carboplatin, 215; P = .67) among the 3 groups. The 5-year progression-free survival rate was 73.3% for the doxorubicin plus cisplatin group, 79.0% for the docetaxel plus cisplatin group, and 73.9% for the paclitaxel plus carboplatin group, while the 5-year overall survival rates were 82.7%, 88.1%, and 86.1%, respectively. CONCLUSIONS AND RELEVANCE: There was no significant difference of survival among patients receiving doxorubicin plus cisplatin, docetaxel plus cisplatin, or paclitaxel plus carboplatin as postoperative adjuvant chemotherapy for endometrial cancer. Because each regimen showed adequate tolerability but different toxic effects, taxane plus platinum regimens may be a reasonable alternative to treatment with doxorubicin plus cisplatin. TRIAL REGISTRATION: UMIN-CTR identifier: UMIN000000522.
引用
- Nomura H, Aoki D, Michimae H, et al. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30896757. doi:10.1001/jamaoncol.2019.0001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。